Accretropin – New Injectable Growth Hormone Approved by FDA

Today, the U.S. Food and Drug Administration (FDA) approved a new recombinant growth hormone manufactured by the Canadian drug company, Cangene, and designed for subcutaneous injection. The brand name for Cangene’s injectable growth hormone is Accretropin. Accretropin has an identical amino acid sequence to natural human growth hormone produced in the pituitary. It was approved for treatment of children with short stature and Turner’s Syndrome (a chromosomal disorder in girls resulting in short stature and infertility). Cangene submitted the new drug application (NDA) to the FDA in July 2006.

 Accretropin joins several other 191-amino acid sequence growth hormone brands currently approved by the FDA including Nutropin AQ, Saizen, Genotropin, Humatrope, Serostim, Zorbtive, Norditropin and Zomacton

Speak Your Mind


Read previous post:
Insulin-like Growth Factor 1 (IGF-1) peptides
Pharmaceutical Company Studying Growth Hormone and IGF-1 Stack

Tercica announced that they just started a Phase II clinical trial examining the efficacy of IGF-1 stacked with human growth...